Pharmacotherapy of Oropharyngeal Candidiasis
PST 06106
Basic Pharmacotherapy
Session 33: Pharmacotherapy of Oropharyngeal Candidiasis
Learning Tasks
By
the end of this session students are expected to be able to:
Define oropharyngeal candidiasis
Explain pathophysiology of oropharyngeal candidiasis
Explain the clinical presentation of oropharyngeal candidiasis
Outline diagnosis of oropharyngeal candidiasis
Describe pharmacological treatment of oropharyngeal candidiasis
Describe the monitoring of oropharyngeal candidiasis therapy
Definition of Oropharyngeal Candidiasis
Oropharyngeal candidiasis
(OPC), or
thrush,
refers to an infection of the oral mucosa.
Candida
is responsible for the majority of
oralfungal
infections, and
C.
albicans
is the principal species causing the infection, commonly referred to as
candidiasis
The infection may extend into the esophagus, causing esophageal candidiasis.
Activity: Buzzing
What
is the pathophysiology of oropharyngeal candidiasis?
Pathophysiology of Oropharyngeal Candidiasis
The pathogenesis of OPC is most clearly elucidated in the setting of HIV infection.
There appear to be several levels of immune defense against the development of OPC in HIV-infected persons, and they involve both systemic and local immunity.
The primary line of host defense against
C.
albicans
is cell-mediated immunity (CMI) at the mucosal surfaces, which is mediated by CD4 T cells.
The efficacy of the CD4 T cells is reduced when the number of cells drops below a protective threshold, and protection against infection becomes dependent on secondary or local immune mechanisms
Pathophysiology of Oropharyngeal
Candidiasis
Cont
….
When the number of CD4 T cells drops too low, recruitment of these cells to the oral cavity is impaired.
The CD4 T-cell count has been considered as the hallmark predictor for development of OPC.
The changeover of the role of
Candida
species from commensal to pathogenic in the human host usually occurs when breakdown in these host defenses occurs.
Other virulence factors are the adhesive ability of
C.
albicans
to epithelial cells and proteins and its ability to invade host cells
by means of phospholipase and proteinase enzymes.
Pathophysiology of Oropharyngeal Candidiasis
Cont
….
This may be one
of the factors leading to OPC in non-HIV-infected individuals.
Other
components of the pathogenesis in the absence of HIV that have been
postulated are the ability of the
Candida
species to adhere to buccal
epithelial cells including those patients receiving broad-spectrum antimicrobial therapy.
Clinical Presentation and Diagnosis of Oropharyngeal Candidiasis
General
The clinical features can be quite diverse
Symptoms
Symptoms are diverse and range from none to sore, painful mouth, burning tongue, metallic taste, and dysphagia and odynophagia with involvement of the hypopharynx
Signs
Signs are variable and can include diffuse erythema and white patches on the surfaces of the buccal mucosa, throat, tongue, or gums; constitutional signs are absent
Clinical Presentation and Diagnosis of Oropharyngeal Candidiasis
Cont
….
Laboratory tests
Scraping of an active lesion for microscopic examination can help confirm the diagnosis (presence of
pseudohyphae
and budding yeast) but is usually not necessary
Cultures are not necessary because isolation of
Candida
species does not distinguish between colonization and true infection; cultures can be taken in patients responding poorly to therapy to determine the infecting species and to predict likely drug resistance
Activity
: Small Group Discussion
What are the drugs treatments for oropharyngeal candidiasis
?
Pharmacological Treatment of Prostate Cancer
The management of OPC should be individualized for each patient, taking into consideration the underlying immune status, other concurrent mucosal and medical diseases, concomitant medications, and exogenous infectious sources.
In HIV-infected patients with inadequately controlled disease, antifungal treatment produces only a transient clinical response, and the relapse rates are higher than in other patient populations.
Topical therapies should be the first choice for milder forms of infections
Therapeutic Options for Mucosal Candidiasis
Monitoring of Oropharyngeal Candidiasis Therapy
Efficacy end points for oropharyngeal and esophageal candidiasis include rapid relief of symptoms and prevention of complications without early relapse after completion of the course of therapy.
Symptomatic relief of presenting signs and symptoms generally occurs within 48 to 72 hours of starting therapy, with complete resolution by 7 to 10 days.
Patients should be advised about the time course and told to return for reassessment when signs and symptoms recur.
It is usually unnecessary for the patient to be reassessed soon after finishing the treatment course.
Monitoring of Oropharyngeal Candidiasis Therapy
Cont
…
However, HIV patients should be questioned and examined for the occurrence of
mucosal
candidiasis
as part of their regular follow-up.
The frequency of monitoring can be more often in neutropenic patients
because
of
concern for dissemination of candidiasis.
During the period of neutropenia, temperature should be monitored daily, as well
as
signs
of dissemination.
Efficacy of the antifungal agent is partly influenced by patient adherence to the medication regimen.
Patients must be counseled on proper administration and dosing, in particular for
topical
agents
Monitoring of Oropharyngeal Candidiasis Therapy
Cont
…
Safety end points include monitoring for occurrence of the relevant drug side effects and drug interactions
Hepatotoxicity can occur when azole therapy is prolonged beyond 7 to 10 days or high doses are used.
Periodic monitoring of liver enzymes (alanine transaminase and aspartate amino-transferase) should be considered, especially if prolonged therapy (longer than 21 days) is anticipated.
Key Points
Oropharyngeal
candidiasis
(OPC), or
thrush,
refers to an infection of the oral mucosa.
Symptoms are diverse and range from none to sore, painful mouth, burning tongue, metallic taste, and dysphagia and odynophagia with involvement of the hypopharynx
The management of OPC should be individualized for each patient, taking into consideration the underlying immune status, other concurrent mucosal and medical diseases, concomitant medications, and exogenous infectious sources
Evaluation
What
is Oropharyngeal Candidiasis?
What is the pathophysiology of Oropharyngeal Candidiasis?
How is Oropharyngeal Candidiasis?
What is the first line treatment of Oropharyngeal Candidiasis?
REFER
Students to Handout 33.1: Risk Factors for the Development of Oropharyngeal and/or Esophageal Candidiasis
References
Wells
BG,
DiPiro
J,
Schwinghammer
T (2013),
Pharmacotherapy Handbook
(6
th
Ed). New York, NY: McGraw-Hill.
DiPiro
JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, (2008):
Pharmacotherapy: A Pathophysiologic Approach
(7
th
ed
): New York, NY: McGraw-Hill.
Katz M D., Matthias KR., Chisholm-Burns M A., Pharmacotherapy(2011)
Principles & Practice Study Guide: A Case-Based Care Plan Approach
: New York, NY: McGraw-Hill.
Schwinghammer
TL, Koehler JM (2009)
Pharmacotherapy Casebook: A Patient-Focused Approach
(7
th
ed
): New York, NY: McGraw-Hill.
Unataka kutumiwa notes hizi kupitia WhatsApp?Kwa notes zilizopangiliwa vizuri kwa kusoma offline au PDF, bonyeza kitufe hapa chini. Ujumbe wenye Level, Semester, Module na Topic utaandaliwa moja kwa moja.TUMIWA NOTES WHATSAPP
